lenalidomide
Not Tagged
['mmsm', 'mds', 'revlimid']
2/44 patients in the ecog phase 2 run-in of revlimid also developed hematologic spms (1 mds and 1 all). important data to discuss regarding risk/benefits before treating asymptomatic people, 50% of whom may never need any treatment #mmsm #ash22
Hematologist/Cancer Doctor/Clinical Researcher @ColumbiaCancer 
#Myeloma #Amyloidosis
Asst. Prof @ColumbiaMed
Host @BloodCancerTalk
COI: https://t.co/du0rVN9gca